Compliance Status
Not Halal
Screened on Oct 9, 2026 · AAOIFI Standard 21
Non-Compliant
Is Aligos Therapeutics, Inc. (ALGS) halal? Not Halal. Based on AAOIFI screening, Aligos Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).
Quote this verdict
HalalScreener rates Aligos Therapeutics, Inc. (ALGS) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Oct 9, 2026. Source: https://halalscreener.app/en/stock/ALGS
Business activity
What the company sells is permissible.
Company debt
Well clear of the limitHow much the company borrows, compared to its total value. AAOIFI allows up to 30%.
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
What this means for you
Most scholars advise not holding ALGS
It does not pass AAOIFI Shariah screening.
See halal alternatives from the same sector further down this page
ALGS: Is Aligos Therapeutics, Inc. Halal?
Aligos Therapeutics, Inc.
$5.34
Market Cap: 33.0M
Get an email if ALGS's halal status changes
We re-screen Aligos Therapeutics, Inc. daily. If the verdict moves, you hear about it the same day.
Free. One click sets it up, and you can unsubscribe any time.
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology
Why this does not pass
- Interest-bearing deposits are over the 30% limit.
- Income from prohibited sources is over the 5% limit.
Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.
Shariah Compliance Status
See which ratio caused the failure.
See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.
AI Compliance Insight
PROInstitutional-grade Shariah analysis
See why ALGS is rated Not Halal with institutional-grade analysis
The verdict above is final and free.
Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.
Screened according to AAOIFI Standard 21
Compliance History
Not Halal, unchanged since Aug 2026.
No status changes recorded since we began tracking.
Tracked since Aug 2026. Updates automatically on each re-screen.
Halal Alternatives in Healthcare
This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:
More Healthcare Stocks
Know the day ALGS's verdict changes
A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.
Frequently Asked Questions
Is Aligos Therapeutics, Inc. (ALGS) halal to invest in?
Why did Aligos Therapeutics, Inc. get a F compliance rating?
What could change Aligos Therapeutics, Inc.'s Shariah verdict?
How often is Aligos Therapeutics, Inc. re-screened for Shariah compliance?
Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.
Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.